{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:42:37Z","timestamp":1765546957143,"version":"3.48.0"},"reference-count":50,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_dmpt-2022-0120_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      Symptomatic remediation from attention deficit hyperactivity disorder (ADHD)-associated traits is achieved by treatment with methylphenidate (MPH)\/atomoxetine (ATX). We have analyzed the association of functional\n                      <jats:italic>CYP2D6<\/jats:italic>\n                      variations, rs1065852, rs3892097, rs1135840, and rs1058164, with ADHD in the Indian subjects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dmpt-2022-0120_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Subjects were recruited following the Diagnostic and Statistical Manual for Mental Disorders. Trait scores were obtained from the Conner\u2019s Parents Rating Scale-Revised. After obtaining informed consent, blood was collected for DNA isolation, and genotyping was performed by PCR or TaqMan-based methods. Probands were treated with MPH or ATX based on age, symptoms, and drug availability. Treatment outcome was assessed using a structured questionnaire. Data obtained was analyzed to identify the association of\n                      <jats:italic>CYP2D6<\/jats:italic>\n                      variations and the\n                      <jats:italic>SLC6A3<\/jats:italic>\n                      rs28363170 with the treatment outcome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dmpt-2022-0120_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The frequency of rs1135840 \u201cG\u201d and rs1065852 \u201cG\u201d was higher in the male ADHD probands. Bias in parental transmission (p=0.007) and association with higher trait scores were observed for rs1065852 \u201cA\u201d. Independent influence of rs1065852 on ADHD was also observed. Probands carrying rs1065852 \u2018GG\u2019, rs1135840 \u2018CG\u2019, and rs28363170 10R exhibited significant symptomatic improvement with MPH, while probands with rs1135840 \u2018CC\u2019 and rs28363170 9R showed improvement after ATX treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dmpt-2022-0120_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      ADHD probands having specific\n                      <jats:italic>CYP2D6<\/jats:italic>\n                      genetic variations respond differentially to pharmaceutical intervention.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/dmpt-2022-0120","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T08:17:59Z","timestamp":1664353079000},"page":"45-56","source":"Crossref","is-referenced-by-count":3,"title":["Post-treatment symptomatic improvement of the eastern Indian ADHD probands is influenced by\n                    <i>CYP2D6<\/i>\n                    genetic variations"],"prefix":"10.1515","volume":"38","author":[{"given":"Mahasweta","family":"Chatterjee","sequence":"first","affiliation":[{"name":"Manovikas Biomedical Research and Diagnostic Centre , Manovikas Kendra , Kolkata , West Bengal , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharmistha","family":"Saha","sequence":"additional","affiliation":[{"name":"Manovikas Biomedical Research and Diagnostic Centre , Manovikas Kendra , Kolkata , West Bengal , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhamita","family":"Maitra","sequence":"additional","affiliation":[{"name":"Department of Radiation Science , Umea University , Umea , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anirban","family":"Ray","sequence":"additional","affiliation":[{"name":"Department of Psychiatry , Institute of Psychiatry , Kolkata , West Bengal , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swagata","family":"Sinha","sequence":"additional","affiliation":[{"name":"Manovikas Biomedical Research and Diagnostic Centre , Manovikas Kendra , Kolkata , West Bengal , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4317-7522","authenticated-orcid":false,"given":"Kanchan","family":"Mukhopadhyay","sequence":"additional","affiliation":[{"name":"Manovikas Biomedical Research and Diagnostic Centre , Manovikas Kendra , Kolkata , West Bengal , India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"2025121207061400917_j_dmpt-2022-0120_ref_001","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Arlington, VA: Author; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_002","doi-asserted-by":"crossref","unstructured":"Gnanavel, S, Sharma, P, Kaushal, P, Hussain, S. Attention deficit hyperactivity disorder and comorbidity: a review of literature. World J Clin Cases 2019;7:2420\u20136. https:\/\/doi.org\/10.12998\/wjcc.v7.i17.2420.","DOI":"10.12998\/wjcc.v7.i17.2420"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_003","doi-asserted-by":"crossref","unstructured":"Bruxel, EM, Akutagava-Martins, GC, Salatino-Oliveira, A, Contini, V, Kieling, C, Hutz, MH, et al.. ADHD pharmacogenetics across the life cycle: new findings and perspectives. Am J Med Genet B Neuropsychiatr Genet 2014;165B:263\u201382. https:\/\/doi.org\/10.1002\/ajmg.b.32240.","DOI":"10.1002\/ajmg.b.32240"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_004","doi-asserted-by":"crossref","unstructured":"Garg, J, Arun, P, Chavan, BS. Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder. Int J Appl Basic Med Res 2015;5:114\u20138. https:\/\/doi.org\/10.4103\/2229-516x.157162.","DOI":"10.4103\/2229-516X.157162"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_005","doi-asserted-by":"crossref","unstructured":"Joseph, A, Ayyagari, R, Xie, M, Cai, S, Xie, J, Huss, M, et al.. Comparative efficacy and safety of attention-deficit\/hyperactivity disorder pharmacotherapies, including guanfacine extended-release: a mixed treatment comparison. Eur Child Adolesc Psychiatr 2017;26:875\u201397. https:\/\/doi.org\/10.1007\/s00787-017-0962-6.","DOI":"10.1007\/s00787-017-0962-6"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_006","doi-asserted-by":"crossref","unstructured":"Ray, A, Maitra, S, Chatterjee, M, Ghosh, P, Karmakar, A, Sinha, S, et al.. Dimorphic association of dopaminergic transporter gene variants with treatment outcome: pilot study in Indian ADHD probands. Meta Gene 2017;11:64\u20139. https:\/\/doi.org\/10.1016\/j.mgene.2016.11.007.","DOI":"10.1016\/j.mgene.2016.11.007"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_007","doi-asserted-by":"crossref","unstructured":"Shah, R, Grover, S, Avasthi, A. Clinical practice guidelines for the assessment and management of attention-deficit\/hyperactivity disorder. Indian J Psychiatr 2019;61(2 Suppl):176\u201393. https:\/\/doi.org\/10.4103\/psychiatry.indianjpsychiatry_543_18.","DOI":"10.4103\/psychiatry.IndianJPsychiatry_543_18"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_008","doi-asserted-by":"crossref","unstructured":"Grizenko, N, Bhat, M, Schwartz, G, Ter-Stepanian, M, Joober, R. Efficacy of methylphenidate in children with attention-deficit hyperactivity disorder and learning disabilities: a randomized crossover trial. J Psychiatr Neurosci 2006;31:46\u201351.","DOI":"10.1139\/jpn.0606"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_009","doi-asserted-by":"crossref","unstructured":"Hodgkins, P, Shaw, M, McCarthy, S, Sallee, FR. The pharmacology and clinical outcomes of amphetamines to treat ADHD: does composition matter? CNS Drugs 2012;26:245\u201368. https:\/\/doi.org\/10.2165\/11599630-000000000-00000.","DOI":"10.2165\/11599630-000000000-00000"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_010","doi-asserted-by":"crossref","unstructured":"Gajria, K, Lu, M, Sikirica, V, Greven, P, Zhong, Y, Qin, P, et al.. Adherence, persistence, and medication discontinuation in patients with attention-deficit\/hyperactivity disorder\u00a0\u2013 a systematic literature review. Neuropsychiatric Dis Treat 2014;10:1543\u201369.","DOI":"10.2147\/NDT.S65721"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_011","doi-asserted-by":"crossref","unstructured":"Toomey, SL, Sox, CM, Rusinak, D, Finkelstein, JA. Why do children with ADHD discontinue their medication? Clin Pediatr 2012;51:763\u20139. https:\/\/doi.org\/10.1177\/0009922812446744.","DOI":"10.1177\/0009922812446744"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_012","doi-asserted-by":"crossref","unstructured":"Tan-Kam, T, Suthisisang, C, Pavasuthipaisit, C, Limsila, P, Puangpetch, A, Sukasem, C. Importance of pharmacogenetics in the treatment of children with attention deficit hyperactive disorder: a case report. Pharmgenomics Pers Med 2013;6:3\u20137. https:\/\/doi.org\/10.2147\/pgpm.s36782.","DOI":"10.2147\/PGPM.S36782"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_013","doi-asserted-by":"crossref","unstructured":"Buitelaar, J, Asherson, P, Soutullo, C, Colla, M, Adams, DH, Tanaka, Y, et al.. Differences in maintenance of response upon discontinuation across medication treatments in attention-deficit\/hyperactivity disorder. Eur Neuropsychopharmacol 2015;25:1611\u201321. https:\/\/doi.org\/10.1016\/j.euroneuro.2015.06.003.","DOI":"10.1016\/j.euroneuro.2015.06.003"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_014","doi-asserted-by":"crossref","unstructured":"Edvinsson, D, Ekselius, L. Long-term tolerability and safety of pharmacological treatment of adult attention-deficit\/hyperactivity disorder: a 6-year prospective naturalistic study. J\u00a0Clin Psychopharmacol 2018;38:370\u20135. https:\/\/doi.org\/10.1097\/jcp.0000000000000917.","DOI":"10.1097\/JCP.0000000000000917"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_015","doi-asserted-by":"crossref","unstructured":"Duong, S, Chung, K, Wigal, SB. Metabolic, toxicological, and safety considerations for drugs used to treat ADHD. Expet Opin Drug Metabol Toxicol 2012;8:543\u201352. https:\/\/doi.org\/10.1517\/17425255.2012.671295.","DOI":"10.1517\/17425255.2012.671295"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_016","doi-asserted-by":"crossref","unstructured":"Lee, J, Grizenko, N, Bhat, V, Sengupta, S, Polotskaia, A, Joober, R. Relation between therapeutic response and side effects induced by methylphenidate as observed by parents and teachers of children with ADHD. BMC Psychiatr 2011;11:70. https:\/\/doi.org\/10.1186\/1471-244x-11-70.","DOI":"10.1186\/1471-244X-11-70"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_017","doi-asserted-by":"crossref","unstructured":"Nebert, DW, Russell, DW. Clinical importance of the cytochromes P450. Lancet 2002;360:1155\u201362. https:\/\/doi.org\/10.1016\/s0140-6736(02)11203-7.","DOI":"10.1016\/S0140-6736(02)11203-7"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_018","doi-asserted-by":"crossref","unstructured":"Ingelman-Sundberg, M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects, and functional diversity. Pharmacogenomics J 2005;5:6\u201313. https:\/\/doi.org\/10.1038\/sj.tpj.6500285.","DOI":"10.1038\/sj.tpj.6500285"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_019","doi-asserted-by":"crossref","unstructured":"Viviani, R, Messina, I, Bosch, JE, Dommes, L, Paul, A, Schneider, KL, et al.. Effects of genetic variability of CYP2D6 on neural substrates of sustained attention during on-task activity. Transl Psychiatry 2020;10:338. https:\/\/doi.org\/10.1038\/s41398-020-01020-z.","DOI":"10.1038\/s41398-020-01020-z"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_020","doi-asserted-by":"crossref","unstructured":"Wang, D, Poi, MJ, Sun, X, Gaedigk, A, Leeder, JS, Sadee, W. Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Hum Mol Genet 2014;23:268\u201378. https:\/\/doi.org\/10.1093\/hmg\/ddt417.","DOI":"10.1093\/hmg\/ddt417"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_021","doi-asserted-by":"crossref","unstructured":"Sakuyama, K, Sasaki, T, Ujiie, S, Obata, K, Mizugaki, M, Ishikawa, M, et al.. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab Dispos 2008;36:2460\u20137. https:\/\/doi.org\/10.1124\/dmd.108.023242.","DOI":"10.1124\/dmd.108.023242"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_022","doi-asserted-by":"crossref","unstructured":"Ingelman-Sundberg, M, Sim, SC. Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system. Biochem Biophys Res Commun 2010;396:90\u20134. https:\/\/doi.org\/10.1016\/j.bbrc.2010.02.162.","DOI":"10.1016\/j.bbrc.2010.02.162"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_023","doi-asserted-by":"crossref","unstructured":"Brown, JT, Bishop, JR, Sangkuhl, K, Nurmi, EL, Mueller, DJ, Dinh, JC, et al.. Clinical pharmacogenetics implementation consortium guideline for Cytochrome P450 (CYP) 2D6 genotype and\u00a0atomoxetine therapy. Clin Pharmacol Ther 2019;106:94\u2013102. https:\/\/doi.org\/10.1002\/cpt.1409.","DOI":"10.1002\/cpt.1409"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_024","doi-asserted-by":"crossref","unstructured":"Taylor, C, Crosby, I, Yip, V, Maguire, P, Pirmohamed, M, Turner, RM. A\u00a0review of the important role of CYP2D6 in pharmacogenomics. Genes 2020;11:1295. https:\/\/doi.org\/10.3390\/genes11111295.","DOI":"10.3390\/genes11111295"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_025","doi-asserted-by":"crossref","unstructured":"Dhuya, M, Pal, MM, Hazra, A, Chatterjee, S, Gogtay, N. Cytochrome P450 2D6 polymorphism in eastern Indian population. Indian J\u00a0Pharmacol 2020;52:189\u201395. https:\/\/doi.org\/10.4103\/ijp.ijp_530_17.","DOI":"10.4103\/ijp.IJP_530_17"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_026","doi-asserted-by":"crossref","unstructured":"Ahmed, S, Zhou, J, Zhou, Z, Chen, SQ. Genetic polymorphisms and in Silico mutagenesis analyses of CYP2C9, CYP2D6, and CYPOR genes in the Pakistani population. Genes 2018;9:514. https:\/\/doi.org\/10.3390\/genes9100514.","DOI":"10.3390\/genes9100514"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_027","doi-asserted-by":"crossref","unstructured":"Hongkaew, Y, Gaedigk, A, Wilffert, B, Ngamsamut, N, Kittitharaphan, W, Limsila, P, et al.. Relationship between CYP2D6 genotype, activity score, and phenotype in a pediatric Thai population treated with risperidone. Sci Rep 2021;11:4158. https:\/\/doi.org\/10.1038\/s41598-021-83570-w.","DOI":"10.1038\/s41598-021-83570-w"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_028","doi-asserted-by":"crossref","unstructured":"Levran, O, Peles, E, Hamon, S, Randesi, M, Adelson, M, Kreek, MJ. CYP2D6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addiction Biol 2013;18:709\u201316. https:\/\/doi.org\/10.1111\/j.1369-1600.2011.00349.x.","DOI":"10.1111\/j.1369-1600.2011.00349.x"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_029","doi-asserted-by":"crossref","unstructured":"Matimba, A, Del-Favero, J, Van Broeckhoven, C, Masimirembwa, C. Novel variants of major drug-metabolizing enzyme genes in diverse African populations and their predicted functional effects. Hum Genom 2009;3:169\u201390.","DOI":"10.1186\/1479-7364-3-2-169"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_030","doi-asserted-by":"crossref","unstructured":"Medhasi, S, Pasomsub, E, Vanwong, N, Ngamsamut, N, Puangpetch, A, Chamnanphon, M, et al.. Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder. Neuropsychiatric Dis Treat 2016;12:843\u201351. https:\/\/doi.org\/10.2147\/ndt.s101580.","DOI":"10.2147\/NDT.S101580"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_031","doi-asserted-by":"crossref","unstructured":"Naveen, AT, Adithan, C, Soya, SS, Gerard, N, Krishnamoorthy, R. CYP2D6 genetic polymorphism in South Indian populations. Biol Pharm Bull 2006;29:1655\u20138. https:\/\/doi.org\/10.1248\/bpb.29.1655.","DOI":"10.1248\/bpb.29.1655"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_032","doi-asserted-by":"crossref","unstructured":"Paradkar, MU, Shah, SAV, Dherai, AJ, Shetty, D, Ashavaid, TF. Distribution of CYP2D6 genotypes in the Indian population\u00a0\u2013 preliminary report. Drug Metab Pers Ther 2018;33:141\u201351. https:\/\/doi.org\/10.1515\/dmpt-2018-0011.","DOI":"10.1515\/dmpt-2018-0011"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_033","doi-asserted-by":"crossref","unstructured":"Suarez-Kurtz, G, Pena, SDJ, Struchiner, CJ, Hutz, MH. Pharmacogenomic diversity among Brazilians: influence of ancestry, self-reported color, and geographical origin. Front Pharmacol 2012;3:191. https:\/\/doi.org\/10.3389\/fphar.2012.00191.","DOI":"10.3389\/fphar.2012.00191"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_034","unstructured":"Umamaheswaran, G, Kumar, DK, Adithan, C. Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes and drug transporters\u00a0\u2013 a review with Indian perspective. Indian J\u00a0Med Res 2014;139:27\u201365."},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_035","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Text Revision Washington, DC: Author; 2000."},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_036","doi-asserted-by":"crossref","unstructured":"Conners, CK, Sitarenios, G, Parker, JD, Epstein, JN. The revised conners\u2019 parent rating scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol 1998;26:257\u201368. https:\/\/doi.org\/10.1023\/a:1022602400621.","DOI":"10.1023\/A:1022602400621"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_037","unstructured":"Barkley, R. Hyperactive children: a handbook for diagnosis and treatment. New York: Guildford Press; 1981."},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_038","doi-asserted-by":"crossref","unstructured":"Miller, SA, Dykes, DD, Polesky, HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215. https:\/\/doi.org\/10.1093\/nar\/16.3.1215.","DOI":"10.1093\/nar\/16.3.1215"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_039","doi-asserted-by":"crossref","unstructured":"Das, M, Mukhopadhyay, K. DAT1 3\u2019-UTR 9R allele: preferential transmission in Indian children with attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2007;144B:826\u20139. https:\/\/doi.org\/10.1002\/ajmg.b.30513.","DOI":"10.1002\/ajmg.b.30513"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_040","doi-asserted-by":"crossref","unstructured":"Dudbridge, F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered 2008;66:87\u201398. https:\/\/doi.org\/10.1159\/000119108.","DOI":"10.1159\/000119108"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_041","doi-asserted-by":"crossref","unstructured":"Barrett, JC, Fry, B, Maller, J, Daly, MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263\u20135. https:\/\/doi.org\/10.1093\/bioinformatics\/bth457.","DOI":"10.1093\/bioinformatics\/bth457"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_042","doi-asserted-by":"crossref","unstructured":"Moore, JH, Gilbert, JC, Tsai, CT, Chiang, FT, Holden, T, Barney, N, et al.. A flexible computational framework for detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human disease susceptibility. J Theor Biol 2006;241:252\u201361. https:\/\/doi.org\/10.1016\/j.jtbi.2005.11.036.","DOI":"10.1016\/j.jtbi.2005.11.036"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_043","unstructured":"Nevels, RM, Weiss, NH, Killebrew, AE, Gontkovsky, ST. Methylphenidate and its under-recognized, underexplained, and serious drug interactions: a review of the literature with\u00a0heightened concerns. Am J Geriatr Psychiatr 2013;16:29\u201342."},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_044","doi-asserted-by":"crossref","unstructured":"Bonnet-Brilhault, F, Broly, F, Blanc, R, Furet, Y, Barth\u00e9l\u00e9my, C, Paintaud, G. An ADHD 6-year-old child ultrarapid metabolizer for CYP2D6. J\u00a0Clin Psychopharmacol 2006;26:442\u20134. https:\/\/doi.org\/10.1097\/01.jcp.0000227352.52288.50.","DOI":"10.1097\/01.jcp.0000227352.52288.50"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_045","doi-asserted-by":"crossref","unstructured":"Ring, BJ, Gillespie, JS, Eckstein, JA, Wrighton, SA. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos 2002;30:319\u201323. https:\/\/doi.org\/10.1124\/dmd.30.3.319.","DOI":"10.1124\/dmd.30.3.319"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_046","doi-asserted-by":"crossref","unstructured":"Michelson, D, Read, HA, Ruff, DD, Witcher, J, Zhang, S, McCracken, J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2007;46:242\u201351. https:\/\/doi.org\/10.1097\/01.chi.0000246056.83791.b6.","DOI":"10.1097\/01.chi.0000246056.83791.b6"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_047","doi-asserted-by":"crossref","unstructured":"Trzepacz, PT, Williams, DW, Feldman, PD, Wrishko, RE, Witcher, JW, Buitelaar, JK. CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. Eur Neuropsychopharmacol 2008;18:79\u201386. https:\/\/doi.org\/10.1016\/j.euroneuro.2007.06.002.","DOI":"10.1016\/j.euroneuro.2007.06.002"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_048","doi-asserted-by":"crossref","unstructured":"Gaedigk, A, Simon, SD, Pearce, RE, Bradford, LD, Kennedy, MJ, Leeder, JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008;83:234\u201342. https:\/\/doi.org\/10.1038\/sj.clpt.6100406.","DOI":"10.1038\/sj.clpt.6100406"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_049","doi-asserted-by":"crossref","unstructured":"Indian Genome Variation Consortium. The Indian Genome Variation database (IGVdb): a project overview. Hum Genet 2005;118:1\u201311.","DOI":"10.1007\/s00439-005-0009-9"},{"key":"2025121207061400917_j_dmpt-2022-0120_ref_050","doi-asserted-by":"crossref","unstructured":"Petrovi\u0107, J, Pe\u0161i\u0107, V, Lauschke, VM. Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe. Eur J Hum Genet 2020;28:88\u201394. https:\/\/doi.org\/10.1038\/s41431-019-0480-8.","DOI":"10.1038\/s41431-019-0480-8"}],"container-title":["Drug Metabolism and Personalized Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2022-0120\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2022-0120\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T07:46:48Z","timestamp":1765525608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2022-0120\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,9,28]]},"published-print":{"date-parts":[[2023,3,14]]}},"alternative-id":["10.1515\/dmpt-2022-0120"],"URL":"https:\/\/doi.org\/10.1515\/dmpt-2022-0120","relation":{},"ISSN":["2363-8915"],"issn-type":[{"type":"electronic","value":"2363-8915"}],"subject":[],"published":{"date-parts":[[2022,9,28]]}}}